Atrophic Vaginitis Treatment in Genitourinary Syndrome of Menopause with Personal History of Breast Cancer

Genitourinary syndrome of menopause (GSM) causing atrophic vaginitis requires careful, individualised management when the patient has a personal history of breast cancer. Treatment selection in this population is shaped directly by that oncological history.

Clinical Scenario

Genitourinary syndrome of menopause (atrophic vaginitis) in a patient with a personal history of breast cancer — a comorbidity that directly governs which interventions are appropriate and how decisions should be reached.

Treatment Approach (partial)

A specific form of local therapy may be considered for these patients — but only within a structured framework of multi-disciplinary shared decision-making. The complete selection criteria, regimen, and clinical algorithm are in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/JU.0000000000004589

For patients with GSM who have a personal history of breast cancer, clinicians may recommend local low-dose vaginal estrogen in the context of multi-disciplinary shared decision-making.

View source ↗